PMID- 22863909
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20151119
IS  - 1552-5279 (Electronic)
IS  - 1552-5260 (Linking)
VI  - 9
IP  - 3
DP  - 2013 May
TI  - Homocysteine, progression of ventricular enlargement, and cognitive decline: the 
      Second Manifestations of ARTerial disease-Magnetic Resonance study.
PG  - 302-9
LID - S1552-5260(12)00021-0 [pii]
LID - 10.1016/j.jalz.2011.11.008 [doi]
AB  - BACKGROUND: Homocysteine may be a modifiable risk factor for cognitive decline 
      and brain atrophy, particularly in older persons. We examined whether 
      homocysteine increased the risk for cognitive decline and brain atrophy, and 
      evaluated the modifying effect of age. METHODS: Within the Second Manifestations 
      of ARTerial disease-Magnetic Resonance study-a prospective cohort study among 
      patients with atherosclerotic disease-longitudinal analyses were performed in 663 
      patients (mean age: 57 +/- 9 years; follow-up: 3.9 +/- 0.4 years). At baseline and 
      follow-up, brain segmentation on magnetic resonance imaging was used to quantify 
      relative (%) cortical, ventricular, and global brain volumes, and z-scores of 
      memory and executive functioning were calculated. Linear regression analysis was 
      used to estimate associations of homocysteine (per standard deviation increase) 
      and hyperhomocysteinemia (HHCY) with brain volumes, memory, and executive 
      functioning at follow-up, adjusted for baseline brain volume, memory, and 
      executive functioning, respectively, and age, sex, and vascular risk factors. 
      Furthermore, interaction terms between homocysteine and age (continuous) were 
      added. RESULTS: Significant interactions were observed between total plasma 
      homocysteine (tHcy) and age with cortical, ventricular, and global brain volume 
      (for all three measures: P < .05), and between HHCY and age with executive 
      functioning (P = .04), and results were stratified by age. In patients aged >/=65 
      years, increasing tHcy level and HHCY were significantly associated with 
      progression of ventricular enlargement (B = 0.07%, 95% confidence interval [CI]: 
      0.01% to 0.13% and B = 0.16%, 95% CI: 0.01% to 0.31%, respectively) and with a 
      decline in executive function (B = -0.29, 95% CI: -0.54 to -0.04 and B = -0.84, 
      95% CI: -1.37 to -0.32, respectively). CONCLUSION: Elevated tHcy was related to 
      progression of ventricular enlargement and increased the risk for a decline in 
      executive functioning in older persons.
CI  - Copyright (c) 2013 The Alzheimer's Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Jochemsen, Hadassa M
AU  - Jochemsen HM
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Kloppenborg, Raoul P
AU  - Kloppenborg RP
FAU - de Groot, Lisette C P G M
AU  - de Groot LC
FAU - Kampman, Ellen
AU  - Kampman E
FAU - Mali, Willem P T M
AU  - Mali WP
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
FAU - Geerlings, Mirjam I
AU  - Geerlings MI
CN  - SMART Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120803
PL  - United States
TA  - Alzheimers Dement
JT  - Alzheimer's & dementia : the journal of the Alzheimer's Association
JID - 101231978
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Aged
MH  - Aging/pathology
MH  - Atherosclerosis/epidemiology/metabolism/pathology
MH  - Atrophy/epidemiology/metabolism/pathology
MH  - Biomarkers/blood
MH  - Cerebral Infarction/epidemiology/metabolism/pathology
MH  - Cerebral Ventricles/*metabolism/*pathology
MH  - Cognition Disorders/epidemiology/*metabolism/*pathology
MH  - Disease Progression
MH  - Executive Function
MH  - Female
MH  - Homocysteine/*blood
MH  - Humans
MH  - Longitudinal Studies
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Risk Factors
FIR - Doevendans, P A
IR  - Doevendans PA
FIR - van der Graaf, Y
IR  - van der Graaf Y
FIR - Grobbee, D E
IR  - Grobbee DE
FIR - Rutten, G E H M
IR  - Rutten GE
FIR - Kappelle, L J
IR  - Kappelle LJ
FIR - Mali, W P Th M
IR  - Mali WP
FIR - Moll, F L
IR  - Moll FL
FIR - Visseren, F L J
IR  - Visseren FL
EDAT- 2012/08/07 06:00
MHDA- 2013/10/23 06:00
CRDT- 2012/08/07 06:00
PHST- 2011/07/26 00:00 [received]
PHST- 2011/11/08 00:00 [revised]
PHST- 2011/11/18 00:00 [accepted]
PHST- 2012/08/07 06:00 [entrez]
PHST- 2012/08/07 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - S1552-5260(12)00021-0 [pii]
AID - 10.1016/j.jalz.2011.11.008 [doi]
PST - ppublish
SO  - Alzheimers Dement. 2013 May;9(3):302-9. doi: 10.1016/j.jalz.2011.11.008. Epub 
      2012 Aug 3.